ENTRY       D06349                      Drug
NAME        Yttrium Y 90 epratuzumab tetraxetan (USAN)
EFFICACY    Antineoplastic, Radioactive agent, Anti-CD22 antibody
  TYPE      Antibody-drug conjugate
COMMENT     Radioimmunotherapy (RAIT) for non-Hodgkin's B-cell lymphoma
TARGET      CD22 (SIGLEC2) [HSA:933] [KO:K06467]
  PATHWAY   hsa04514(933)  Cell adhesion molecules
            hsa04640(933)  Hematopoietic cell lineage
            hsa04662(933)  B cell receptor signaling pathway
BRITE       Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Cell adhesion molecules: Ig superfamiy
               SIGLEC family
                CD22 (SIGLEC2)
                 D06349  Yttrium Y 90 epratuzumab tetraxetan (USAN)
DBLINKS     CAS: 501423-25-2
            PubChem: 47208006
///
